Efficacy and Safety assessments of a peritoneal dialysis solution containing Glucose, Xylitol and L-Carnitine compared to standard PD solutions in Continuous Ambulatory Peritoneal Dialysis (CAPD) - ND

IPERBOREAL PHARMA0 个研究点目标入组 13 人开始时间: 2010年11月8日最近更新: 2024年3月12日

试验速览

暂无简介。

•For inclusion in the study, patients of both genders must fulfill the following criteria, verified during the screening period: 1. Age =18 years; 2. Diagnosis of ESRD treated for at least three month with CAPD, as stated by the medical staff of the center; 3. Stable clinical condition within four weeks before screening period, certified by medical/surgical history, physical examination and laboratory exploration; 4. Hemoglobin level =9g/dL; 5. Absence of acute peritonitis and/or peritoneal catheter infection (either exit site or subcutaneous tunnel) episodes within three months before selection; 6. To understand and sign an informed consent form. For patients who will be included in Group B, the following criteria must be fulfilled too: 7. Be treated with Extraneal (nocturnal exchange bag solution) for at least 1 month 8. Be treated with 1; 2 or 3 diurnal exchange bag solutions (solution bags with 1,5% glucose) and one nocturnal exchange bag solution with icodextrin (Extraneal).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Patients who fulfill one or more of the following criteria will not be enrolled in the study: 1. History of alcohol or drug abuse in the last six months before selection for the study; 2. Androgen therapy in the last six months before selection; 3. Active infections; 4. History of congestive heart failure stage III and IV NYHA; 5. History of major cardiovascular events like stroke, acute myocardial infarction, coronary or other arterial revascularization procedures in the last three months before selection; 6. Clinically relevant cardiac arrhythmia; 7. Clinically relevant abnormalities of functional hepatic tests; 8. Therapy with L-carnitine or its derivatives in the last three months before selection; 9. Pregnancy, lactating women or female subjects of childbearing potential who do not use an effective method of contraception; 10. Presence of relevant chronic medical conditions that could suggest exclusion of patient from the study or could interfere with assessment of study parameters, especially if the life expectation is less then one year; 11. Participation in another clinical study within the past month; 12. Known allergic reactions to L-carnitine or xylitol.

发起方

IPERBOREAL PHARMA